We have recently identified a candidate gene for rat genetic hypertension by identifying an mRNA species that shows markedly higher expression in the kidneys of spontaneously hypertensive rats than in those of Wistar-Kyoto rats. By using a restriction fragment length polymorphism, we carried out cosegregation analyses between the genotype of the SA gene and blood pressure in three F 2 cohorts and observed significant effects of the SA gene on blood pressure in all of those cohorts. In the present study, we have isolated a human counterpart of the rat SA gene to investigate the possible association between the human SA gene and human essential hypertension. The deduced amino acid sequence from the isolated human SA cDNA consisted of 578 amino acid residues and had slight homology to a bacterial enzyme, acetylcoenzyme A synthase. The human gene was mapped to the human chromosome 16 with the use of a rodent/human E ssential hypertension is a polygenic, heterogeneous, and multifactorial disease, and its pathogenesis, which provides a theoretical background to rational therapy, remains to be fully clarified. Genetic analyses have demonstrated that blood pressure is a quantitative trait in which several genes may be involved. Twenty percent to 40% of blood pressure variation in the general population can be attributed to genetic factors.
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Abstract We have recently identified a candidate gene for rat genetic hypertension by identifying an mRNA species that shows markedly higher expression in the kidneys of spontaneously hypertensive rats than in those of Wistar-Kyoto rats. By using a restriction fragment length polymorphism, we carried out cosegregation analyses between the genotype of the SA gene and blood pressure in three F 2 cohorts and observed significant effects of the SA gene on blood pressure in all of those cohorts. In the present study, we have isolated a human counterpart of the rat SA gene to investigate the possible association between the human SA gene and human essential hypertension. The deduced amino acid sequence from the isolated human SA cDNA consisted of 578 amino acid residues and had slight homology to a bacterial enzyme, acetylcoenzyme A synthase. The human gene was mapped to the human chromosome 16 with the use of a rodent/human E ssential hypertension is a polygenic, heterogeneous, and multifactorial disease, and its pathogenesis, which provides a theoretical background to rational therapy, remains to be fully clarified. Genetic analyses have demonstrated that blood pressure is a quantitative trait in which several genes may be involved. Twenty percent to 40% of blood pressure variation in the general population can be attributed to genetic factors. 1 By identifying the major genetic 'factors in hypertension, we could provide a more reasonable therapeutic approach to this major public health problem.
Recently, we have identified a candidate gene for rat genetic hypertension, termed SA, by identifying an mRNA species that shows markedly higher expression in the kidneys of spontaneously hypertensive rats (SHR) than in those of Wistar-Kyoto (WKY) rats. 2 With the use of a restriction fragment length polymorphism (RFLP) in the rat SA gene, cosegregation analyses were carried out in three cohorts of F 2 rats, and significant effects of the genotype of the SA gene on blood pressure were observed in all of those populations. 3 -5 The expression level of the SA gene in the central nervous system is genetically determined, and interestingly, the expression level in the brain of SHR is markedly lower than in that of WKY rats. 46 These experimental findings strongly suggest that the SA gene is one of the genes responsible for hypertension in SHR, although the SA gene may be just closely linked to the true hypertensive gene in the chromosome. The SA gene was mapped to the rat chromosome 1 between the leukosialin and insulin-like growth factor genes.
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In the present study, we have isolated a human counterpart of the rat SA cDNA to investigate the possible association between the SA gene or the SA gene locus and human essential hypertension. This is the most important issue to be addressed because genetically hypertensive rat models are not necessarily homologous to human essential hypertension. For example, the angiotensin I-converting enzyme locus on the rat chromosome 10 was clarified to contain a gene influencing blood pressure under salt loading conditions, 78 but this locus was concluded to play a small role in human essential hypertension. 9 ' 10 Therefore, we searched for polymorphisms of the SA gene and carried out an association study between a polymorphism and human essential hypertension.
Methods

Isolation and Characterization of the Human cDNA for the SA Gene
A human liver cDNA library constructed in a plasmid vector pDR2 (Clontech) was screened with the rat SA cDNA fragment. Replica filters were prepared with nylon membranes (Pall Biosupport Co). Prehybridization and hybridization were carried out at 60°C in a solution containing 6x SSC (0.9 mol/L NaCl, 0.09 mol/L sodium citrate), 1% sodium dodecyl sulfate (SDS), 50 mmol/L sodium phosphate buffer (pH 7.0), and 100 Hg/mL salmon sperm DNA. The "P-labeled rat SA cDNA probe was prepared by nick translation (specific activity >2xlO" cpm/fig). Hybridization was carried out for 6 to 12 hours in the same solution containing the labeled probe (5 ng/mL). Filters were washed five times for 30 minutes each at 60°C in a solution containing 2x SSC and 0.1% SDS. Out of 100 000 clones screened, 2 positive clones were isolated, and the sequence of the clone with the longer insert was determined on both strands by the dideoxy chain termination method using a Bcabest sequencing kit (Takara Shuzo Co Ltd). The chromosomal location of the human SA gene was determined with the use of a rodent/human somatic cell hybrid panel (BIOSMAP somatic cell hybrid PCRable DNAs, BIOS Corp). One hundred nanograms of each DNA (20 hybrid cells) was amplified in a total volume 25 /iL containing 50 mmol/L KC1, 5 mmol/L Tris-Cl, 0.01% gelatin, 2.5 mmol/L MgCl 2 , 0.2 mmol/L deoxynucleoside 5'-triphosphate, 20 pmol of each primer (see below), and 0.5 U of Taq DNA polymerase (Perkin-Elmer Cetus). The sense primer was 5'-GCTTCCAACAAGACTGATGCTAGC-3', and the reverse primer was 5'-CTCTGGAATCCCCAGTTTGAA-GTCCTG-3'. The amplification profile included 1 minute denaturation at 95°C, followed by 35 cycles of denaturation at 95°C for 1 minute, annealing at 58°C for 1 minute, and polymerization at 74°C for 1 minute. The polymerase chain reaction (PCR) products were resolved on 1.5% agarose gel.
DNA Studies
Genomic DNA was extracted from peripheral blood leukocytes by standard methods. to search for polymorphisms. The resulting fragments separated on 0.7% agarose gel were transferred to nylon filters (Hybond N+, Amersham Japan) and were hybridized to the full-length human SA cDNA fragment. Filters were prehybridized with a solution containing 10% SDS, 7% polyethylene glycol 8000,50 mmol/L sodium phosphate buffer (pH 7.0), and 100 /ig/mL salmon sperm denatured DNA at 65°C for 3 hours and then hybridized with the 32 P-labeled human SA cDNA fragment prepared by the random primer method using a kit (Bcabest labeling kit, Takara Shuzo Co Ltd) (specific activity >8x 10 s cpm//ig) for 12 hours in the same solution. The filters were washed three times for 20 minutes each with 2x SSC containing 0.1% SDS and twice for 20 minutes with 0.2 x SSC containing 0.1% SDS at 65°C. The bands were visualized by autoradiography. Chemical reagents not specifically indicated were obtained from Nacalai Tesque Inc.
Subjects
All subjects analyzed in the present study were from our outpatient clinic. The criteria for essential hypertension included (1) onset of hypertension between 20 and 60 years of age, (2) established hypertension defined by a systolic and diastolic blood pressure more than 160 and 95 mm Hg, respectively, on two separate occasions without antihypertensive treatment, (3) at least one hypertensive individual among first-and second-degree relatives, (4) absence of secondary hypertension, diagnosed by a thorough workup when clinically indicated, and (5) no major cardiovascular complications except left ventricular hypertrophy and no systemic diseases such as overt diabetes mellitus at the initial diagnosis. The criteria for the normotensive control group included (1) age between 35 and 65 years, (2) systolic and diastolic blood pressure less than 135 and 85 mm Hg, respectively, on two separate occasions, (3) no distinct disease or history of serious disease, and (4) no strong genetic predisposition for hypertension. When both parents were identified as hypertensive, those subjects were considered as having a strong genetic predisposition for hypertension. Subjects were told of the purpose of the present study and agreed to supply 4 mL of their blood. Based on the above criteria, 247 subjects were chosen by staff doctors in our department. All sample DNAs were subjected to Southern analyses. Precise subject information was collected from outpatient charts by a specialist in cardiovascular disease (N.O.) who was unaware of the Southern data. Eighty-nine subjects (50 men and 39 women, 50.8±8. 9 [SD] years of age) were classified as hypertensive and 81 (50 men and 31 women, 54.1 ±8.8 years) as normotensive. Another 77 subjects (51 men and 26 women, 53.3±12.3 years) were classified as "Other" and could not be included in the hypertensive or normotensive group because of several reasons, including borderline hypertension (systolic blood pressure more than 140 and/or diastolic blood pressure more than 90 mm Hg), hypertension recognized above 60 years of age, hypertension with no evident family history, normotension with a strong family history of hypertension, hypertension with renal damage in which hypertension might be of renal origin, idiopathic hyperaldosteronism, renovascular hypertension, history of myocardial infarction or cerebrovascular accident, atrial fibrillation or other types of arrhythmia, valvular diseases, hypertrophic or dilated cardiomyopathy, and subjects out of the age range of the study criteria. The relatively high incidence of cardiovascular diseases in this group (the Other group) was due to the specialty of our department (cardiology).
Statistical Analysis
A x 1 analysis (2x3 or 3x3 contingency table) was used to test the significance of differences in frequency. One-or two-way ANOVA was used for comparison of various phenotypes among the groups with a different SA genotype. Fig 1 shows the sequence of the human SA cDNA. The deduced amino acid sequence of the human SA consisted of 578 amino acid residues and 84% amino acid identity with the rat SA. The calculated molecular weight was 65.4 kD, and the isoelectric point was 9.26. Sequence homology was searched in the EMBL/GenBank database, and the acetylcoenzyme A synthetase 11 was found to have 30.6% identity with the human SA. Confined to the carboxy terminal portion (residue 450-578), up to 42% identity was obtained (Fig 2) . Hydrophobic analysis of the putative SA gene product predicted an existence of a leader sequence in its amino terminus. The site for cleavage was predicted according to von Heijne, 12 and the predicted site is indicated by the arrow (Fig 1) .
Results
Sequence of the Human SA cDNA
Pst I Polymorphism of the Human SA Gene
Aliquots of DNA of 12 unrelated individuals were digested with 15 different restriction enzymes, and RFLPs were found with Pst I, Hindi, and Taq I. Because the rare allele frequencies detected with Taq I and Hindi were very low (1 in 24 individuals), these RFLPs were excluded from the present analyses. With Pst I digestion, three types of restriction patterns were obtained (Fig 3) : the first type with a 1.8-, 4-, and 7-kb fragment; the second type with a 1.8-and 4-kb fragment and without a 7-kb fragment; and the third type with only a 7-kb fragment. The intensity of the 7-kb fragment in the first type is less than that in the third type. Therefore, the 7-kb fragment seems to have an internal Pst I site in some individuals. We concluded that the Pst I restriction pattern giving 1.8-and 4-kb fragments and a 7-kb fragment of a reduced intensity was a heterozygous pattern. The Pst I restriction pattern with 1.8-and 4-kb fragments is referred to as allele A2, and the pattern without these fragments is referred to as allele Al. Analyses in two pedigrees with a 5' probe that covered nucleotide numbers -5 1 to 855 and that de- 190  200  210  220  230  240  ENLHSKLIVSENSREGWGNLKELMKHASDSHTCVKTKHNEIMAIFFTSATSGWPKMSAHT   LVYKRTGAEVPWTEGRDIWWHEEVEKYPAYIAPDSVNSEDPLFLLYTSGSTGKPKGVMHT  240  250  260  270  280  290  250  260  270  280  290  HSSFGLGLSVNGRFWLDLTPSDVMWNTSDTGWAKSAWSSVFSPWIQGAC-VFTHHLPRFE   TAGYLLGAAMTGKYVFDIHDDDRYFCGGDVGWITGHTYWYAPLLLGVSTWFESTPAYP  300  310  320  330  340  350  300  310  320  330  340 tected the 7-kb fragment and the fragment just below it (a 6.5 -kb fragment) confirmed that the Al and A2 patterns were really allelic variations (data not shown). This 5' probe could detect the 7-and 6.5-kb fragments in the A1A1 genotype; the 7-kb fragment, with a reduced intensity, the 6.5-, 4-, and 1.8-kb fragments in the A1A2 genotype; and the 6.5-, 4-, and 1.8-kb fragments in the A2A2 genotype.
Chromosomal Localization of the Human SA Gene
Chromosomal localization of the human SA gene was determined with the use of the rodent/human hybrid cell panel. The set of primers indicated in Fig 1  could successfully amplify the human genome region but not the mouse or hamster counterpart. The 184-bp fragment exactly corresponding to the cDNA sequence, which was confirmed by restriction mapping and Southern blot hybridization, was amplified from the DNAs isolated from the two hybrid cells that contained human chromosome 16 but was not amplified from the DNAs isolated from other hybrid cells that did not contain human chromosome 16. The human SA gene was concluded to be on chromosome 16. Association Study Between the Pst I Polymorphism and Hypertension Of our 247 subjects, 89 were classified as hypertensive, 81 as normotensive, and 77 as Other (see "Methods"). The genotypes of the subjects are summarized in the Table. A significant difference in the frequencies of the genotypes was observed among the three groups (* 2 =21.15, i>=.003). The A2 allele frequency in the hypertensive group was 0.27, and that in the normotensive group was 0.09. Thus, the A2 allele frequency was significantly higher in the hypertensive than the normotensive group (/ > =.0001). Seventeen subjects in the Other group had borderline hypertension. When those subjects were included in the hypertensive group, the A2 allele frequency was 0.25, which was still significantly higher than that in the normotensive group (P=.00O2).
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Various phenotypic values including body mass index, plasma cholesterol level, and fasting blood glucose level were compared among the hypertensive subjects with the different SA genotypes. No significant effects of the genotype of the SA gene on these phenotypes were observed (data not shown).
Discussion
SA Gene as a Candidate Gene for Genetic Hypertension
The SA gene was first identified by its great differential expression in SHR kidneys. 2 The functions of the SA gene product(s) were not known. To confirm whether the differential expression observed between SHR and WKY rats was due to just a strain difference or was involved in the pathogenesis of hypertension, a genetic cosegregation analysis was carried out. The SHR allele of the SA gene detected with the restriction enzyme Stu I did cosegregate with higher blood pressure in an F 2 rat population derived from SHR and WKY rats. 3 Subsequent cosegregation analyses using different crosses all indicated that the SA gene locus had some effects on blood pressure. 4 -31314 The rat SA gene was mapped to the rat chromosome 1, 4 cM apart from the leukosialin gene and 9 cM apart from the insulin-like growth factor gene. 5 Because no significant association was observed between the leukosialin or insulin-like growth factor genes and blood pressure, the candidate gene for SHR hypertension was considered to be very close to the SA gene. 5 This speculation was further confirmed with the large F 2 cohort derived from SHR and WKY rats.
14 The expression of the SA gene was detected in the kidney, liver, and central nervous system. 414 Moreover, antihypertensive treatment in SHR could modulate the expression of the SA gene. 2 Taken together, these results show that the SA gene itself can be considered a candidate gene for rat genetic hypertension.
Sequence and Chromosomal Location of the SAGene
The sequence of the rat SA gene in our preceding report corresponded to a minor transcript of the SA gene. 2 The sequence of the major transcript was already reported, in which an additional 102-bp nucleotide sequence was included. 13 The sequence of the human SA cDNA determined in the present study corresponded to the major transcript of the rat SA gene and was highly homologous to the rat SA cDNA. A sequence homology search in the EMBL/GenBank database revealed that the predicted protein had 30% amino acid identity with a bacterial enzyme acetylcoenzyme A synthase, which, at present, gave no clue to the functions of the SA gene products.
The human SA gene was mapped to the human chromosome 16. This was confirmed not only by the PCR method but also by Southern blot analysis (data not shown). In the rat, the SA gene was mapped to the rat chromosome 1, 4 cM apart from the leukosialin gene. The human leukosialin gene was mapped to the human chromosome 16pll.2-qll.2 region. 15 Thus, our result that the human SA gene was on the human chromosome 16 was consistent with the rat data.
In the Southern analysis of the human SA gene with Pst I, multiple bands were detected with the whole cDNA probe. This might indicate that the SA gene is one of the members of a gene family. However, in the Southern analysis of the rodent/human hybrid cell panel, the hybrid cell containing the human chromosome 16 gave all the signals observed in the Southern blot analysis of human genomic DNA (data not shown). Therefore, there are two possible explanations for the multiple bands in the Southern blot. One is that the human SA gene might be large and interspersed with multiple introns. The other is that the human SA gene might be a member of a multigene family, and all the members might exist on the human chromosome 16.
Association of the Genotype of the SA Gene With Higher Blood Pressure
Essential hypertension is a heterogeneous group of disorders. Specific subtypes of essential hypertension might be categorized according to onset age, gender, race or genetic background, sodium sensitivity, 26 and lipid profile. 27 We compared several phenotypic values including body mass index, plasma cholesterol level, and fasting blood glucose level among the hypertensive patients with different genotypes of the SA gene, and no significant correlation between those phenotypes and the genotypes of the SA gene was observed. Finding an association between the genotype of the SA gene and an intermediate phenotype for hypertension will help in identifying a function of the SA gene product. Because our criteria focused mainly on middle-aged hypertensive subjects without severe complications such as cerebrovascular accident and renal damage or without any systemic disease such as overt diabetes mellitus, the hypertensive subjects in the present study might be considered a specific subgroup of essential hypertensive patients. Whether the RFLP with Pst I of the SA gene is associated with hypertension defined from other points of view awaits further investigation.
The control group consisted of healthy adults between 35 and 65 years of age whose blood pressures were measured repeatedly on separate occasions to be normotensive. Although some individuals in this group in their 30s or 40s may develop hypertension in their 50s, this group is considered to consist of those individuals at low risk for developing essential hypertension. The A2 allele frequency in the Other group was 0.16, which was significantly higher than that in the control group. The Other group included 17 borderline hypertensive subjects, 16 hypertensive subjects recognized above 60 years of age, and 18 subjects with myocardial infarction. Because blood pressure values of the subjects with myocardial infarction before recognition of the disease were not measured in our outpatient clinic, those subjects were categorized as the Other group. However, some of the subjects with myocardial infarction had a history of hypertension.
Limitations of the Present Study
Although the present result suggests an importance of the SA gene locus in essential hypertension in a Japanese population, we cannot conclude the SA gene is one of the genes responsible for essential hypertension. We should bear in mind that a positive association could be explained by the effect of another gene linked at some distance to the SA gene. Also, there are many pitfalls in linkage and association studies. Different conclusions might be drawn from populations with different genetic backgrounds, as observed in rat studies. 4 - 13 For a definitive conclusion, clarification of the functions of the SA gene product(s) will be necessary.
In summary, the present results provide favorable evidence that the SA gene is a candidate gene for human essential hypertension and provide a starting point for future studies.
